Post-earnings recap
Reported
Wed, Aug 5, 2026
EPS actual
$-0.62
EPS est.
$-0.64
EPS surprise
+2.82%
1-day move
+1.04%
Kymera Therapeutics reported a narrower-than-expected loss per share, which led to a slight increase in the stock price by 1.04%. However, there was no revenue reported or guidance provided, leaving investors without a clear outlook for the future. The positive EPS surprise may indicate some operational efficiency, but the lack of revenue details raises questions about overall performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.62 | N/A | +2.82% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based solely on numerical results.
Kymera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies to treat various diseases by harnessing the body's natural immune system. With a market cap of $10 billion, it operates in the health care sector, which is increasingly important as the demand for advanced medical treatments continues to grow.
Last quarter
In Q1 2026, Kymera reported an EPS of -$0.71, which was better than the expected -$0.89, resulting in a positive surprise. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.
EPS beat streak
2Q
EPS beat rate
50%
Avg EPS surprise
-5.73%
Avg 1-day reaction
-2.69%
Investors are cautiously optimistic about Kymera's upcoming earnings report, especially given the recent EPS surprise. However, the lack of revenue guidance adds a layer of uncertainty.
Bull case
If Kymera can demonstrate strong revenue growth and continued improvement in EPS, it could signal a solid recovery and attract more investors.
Bear case
Conversely, if the company fails to meet expectations or provides weak guidance, it may lead to a decline in investor confidence and stock price.
The print will turn on these.
Q1
What will the revenue figures be for Q2-2026?
Revenue is critical for understanding the company's growth trajectory and overall financial health, especially after the recent EPS surprise.
Q2
Will management provide guidance for future quarters?
Guidance is essential for setting investor expectations and can significantly impact stock performance.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The Street may be underestimating the potential for revenue growth given recent advancements in Kymera's pipeline, which could lead to better-than-expected results.
Supporting evidence
The recent EPS surprise indicates that the company is performing better than analysts anticipated.
Options pricing suggests a significant move, indicating that traders expect volatility and potential positive outcomes.
Key risk
If revenue comes in significantly above expectations, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance hinges on revenue growth and management's guidance, which are crucial for investor confidence.
Bull confirmed if
A revenue growth rate of over 20% year-over-year would confirm the bullish outlook.
Bear confirmed if
If revenue declines or fails to meet expectations, it would confirm the bearish outlook.
What the market is pricing for the move.
Implied Move
±23.64%
Historical Avg
±4.2%
The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.
Options are pricing ±23.6% while KYMR has averaged ±4.2% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
34.0%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$3.4M
30,000 sh
1 insider
Net
$3.4M
Net selling
Most Active Insiders· 6 open-market trades
$3.4M
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
119.36%
of float
Insider
2.12%
of float
Holders
397
institutions
Top Holders· as of Jun 2026
FMR, LLC
12,349,256 sh · $1.3B
14.85%
5.5%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Kymera beats expectations and raises guidance, history suggests the stock could rise by an average of 2.16% on the day.
In line / cautious
If results are in line with expectations but management is cautious, the stock may see a muted reaction.
Miss
If the company misses expectations, history suggests a potential decline of around 4.14% on the day.
The lines on the call that would change the story.
Recent Transactions
Oct 1, 2026 · @ $115.40
8,230 sh
$949,742.00
Oct 1, 2026 · @ $114.43
7,601 sh
$869,782.43
Oct 1, 2026 · @ $112.42
5,506 sh
$618,984.52
Oct 1, 2026 · @ $113.24
4,876 sh
$552,158.24
Oct 1, 2026 · @ $111.44
3,525 sh
$392,826.00
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Baker Bros. Advisors, LP
8,657,242 sh · $938.0M
10.41%
Flat
Avoro Capital Advisors LLC
7,474,747 sh · $809.9M
8.99%
Flat
Price (T.Rowe) Associates Inc
7,112,980 sh · $770.7M
8.55%
17.4%
T. Rowe Price Investment Management, Inc.
6,257,261 sh · $678.0M
7.53%
14.5%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.